Familial Adenomatous Polyposis (FAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Familial adenomatous polyposis (FAP) is an inherited condition that primarily affects the gastrointestinal tract. This condition causes hundreds or thousands of polyps to form inside the colon and rectum. This condition is also known as hereditary polyposis of the colorectum, Gardner's syndrome, and familial polyposis. Nearly 100% progression to colorectal cancer (CRC) by the age of 35–40 yr and a heightened risk of various other malignancies. Familial adenomatous polyposis (FAP) is a highly penetrant autosomal-dominant disorder caused by a germline mutation in the adenomatous polyposis coli (APC) gene, located on chromosome 5q21. Over 700 different disease-causing APC mutations have been reported to date. However, the most common germline mutation involves the introduction of a premature stop codon, either by a nonsense mutation (30%), frameshift mutation (68%), or large deletion (2%), leading to truncation of the protein product in the C-terminal region.

·       The birth frequency of Familial adenomatous polyposis (FAP) in the USA and European populations is estimated at roughly 1.5 in 15,000 to 1.89 in 18,000 live births, respectively. It is also responsible for less than 1% of all CRC cases.

 

Thelansis’s “Familial Adenomatous Polyposis (FAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Adenomatous Polyposis (FAP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Familial Adenomatous Polyposis (FAP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Familial Adenomatous Polyposis (FAP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Familial Adenomatous Polyposis (FAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Familial Adenomatous Polyposis (FAP), Familial Adenomatous Polyposis (FAP) market outlook, Familial Adenomatous Polyposis (FAP) competitive landscape, Familial Adenomatous Polyposis (FAP) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)